Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.
Latest website image capture
Clouds background image

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Results section has been added, including primary and secondary outcomes (ORR, DCR, DoR, PFS, OS) and updated study dates reflecting posted results.
    Difference
    0.4%
    Check dated 2025-10-28T02:45:59.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    Summary: The page now displays a funding-status notice and updates the version to v3.2.0, replacing v3.1.0.
    Difference
    2%
    Check dated 2025-10-06T15:50:36.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0, indicating a newer release.
    Difference
    0.1%
    Check dated 2025-09-29T09:46:30.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Upgrade to v3.0.2 from v3.0.1; removal of the 'Back to Top' element and no changes to core content.
    Difference
    0.1%
    Check dated 2025-09-14T23:30:50.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.1%
    Check dated 2025-09-07T20:09:09.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of specific facility names and locations in South Korea and Turkey, as well as new chemical compounds and a revision update to version 3.0.0.
    Difference
    3%
    Check dated 2025-08-31T12:39:41.000Z thumbnail image

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.